BioWorld - Tuesday, March 17, 2026

Articles Tagged with ''MSD''

Two arrows in opposite directions

GC Cell's shares drop as MSD terminates $1.8B deal with Artiva

June 27, 2024
By Marian (YoonJee) Chu
Merck Sharp & Dohme Corp. (MSD), known as Merck & Co. Inc. in the U.S. and Canada, terminated its potential $1.86 billion deal with San Diego-based Artiva Biotherapeutics Inc. for novel chimeric antigen receptor-natural killer cell therapies. GC Cell disclosed news of the terminated deal on the Korea Exchange near market close of June 25, saying it was notified by Artiva after the decision was reached by MSD’s internal decision makers.
Read More

MSD, Roche highlight new sub analysis data at ESMO Asia in Asia-prevalent cancers

Jan. 2, 2024
By Tamra Sami
MSD had a banner year at the ESMO Asia Congress earlier this month, presenting 14 abstracts on eight different types of cancers, including gastric, esophageal, colorectal, biliary tract, kidney, urothelial, breast and gynecological cancers. Ten of these studies were focused on Asian-related data. Roche AG, meanwhile, presented Asia-specific results from the phase III Alina study in patients with ALK-positive early stage non-small-cell lung cancer.
Read More

MSD, Roche highlight new sub analysis data at ESMO Asia in Asia-prevalent cancers

Dec. 28, 2023
By Tamra Sami
MSD had a banner year at the ESMO Asia Congress earlier this month, presenting 14 abstracts on eight different types of cancers, including gastric, esophageal, colorectal, biliary tract, kidney, urothelial, breast and gynecological cancers. Ten of these studies were focused on Asian-related data. Roche AG, meanwhile, presented Asia-specific results from the phase III Alina study in patients with ALK-positive early stage non-small-cell lung cancer.
Read More